See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: March 17 2006

Heart Disease Hot Flash Allergy

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Heart Disease

Radiant Research currently has a study enrolling overweight men and women who have heart disease risk factors.

The purpose of this study is to evaluate the safety and effectiveness of an investigational medication and its ability to treat blockage in the heart's blood vessels.

In order to qualify for this study, you must be a male with a waist circumference larger than 40 inches or a woman with a waist circumference larger than 35 inches.

The research site is in Lakewood, Wash.

More Information

Please see


Hot Flash

A clinical research trial is underway, comparing a lower dose of a medication approved by the U.S. Food and Drug Administration and placebo for the relief of moderate-to-severe hot flashes.

Qualified candidates should be healthy females, ages 30-80. Qualified study participants will receive compensation for time and travel, study-related medical care, and study medication at no cost.

Research site is in Philadelphia, Pa.

More Information

Please see



The Clinical Research Center of St. Louis, on the campus of Barnes-Jewish hospital, is conducting a research study of an investigational medication for people experiencing nasal allergy symptoms.

Qualified candidates will receive study-related medical procedures, such as skin testing, lab work, EKGs and physical exams at no cost. Reimbursement for time and travel is provided.

The research site is in St. Louis, Mo.

More Information

Please see


Copyright 2006 CenterWatch. All rights reserved.

Consumer News


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.